Literature DB >> 15774620

ADAMTS13 turns 3.

Gallia G Levy1, David G Motto, David Ginsburg.   

Abstract

It has now been 3 years since the von Willebrand factor (VWF)-cleaving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identified as ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13). More than 50 ADAMTS13 mutations resulting in familial TTP have been reported. Considerable progress has also been realized toward understanding the role of ADAMTS13 in normal hemostasis, as well as the mechanisms by which ADAMTS13 deficiency contributes to TTP pathogenesis. Measurement of ADAMTS13 activity in TTP and other pathologic conditions also remains a focus of a substantial clinical research effort. Building on these studies, continued investigation of ADAMTS13 and VWF holds considerable promise for advancing the understanding of TTP pathogenesis and should lead to improved diagnosis and treatment for this important hematologic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774620     DOI: 10.1182/blood-2004-10-4097

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  The management of immune thrombocytopenic purpura.

Authors:  B I Chosamata
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

2.  Localization of blood proteins thrombospondin1 and ADAMTS13 to cerebral corpora amylacea.

Authors:  He Meng; Xiaojie Zhang; Mila Blaivas; Michael M Wang
Journal:  Neuropathology       Date:  2009-04-28       Impact factor: 1.906

3.  ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.

Authors:  Shangbin Yang; Ming Jin; Shili Lin; Spero Cataland; Haifeng Wu
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 4.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

5.  Expression of ADAMTS-2, -3, -13, and -14 in culprit coronary lesions in patients with acute myocardial infarction or stable angina.

Authors:  Cheol Whan Lee; Ilseon Hwang; Chan-Sik Park; Hyangsin Lee; Duk-Woo Park; Su-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seung-Jung Park
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

6.  Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.

Authors:  Shuichi Ito; Kenichi Okuyama; Tomoko Nakamura; Jun-Ichi Tetanishi; Kazuo Saito; Masanori Matsumoto; Yoshihiro Fujimura; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

Review 7.  Endothelial cells and thrombotic microangiopathy.

Authors:  David Motto
Journal:  Semin Nephrol       Date:  2012-03       Impact factor: 5.299

8.  Hypochlorous acid generated by neutrophils inactivates ADAMTS13: an oxidative mechanism for regulating ADAMTS13 proteolytic activity during inflammation.

Authors:  Yi Wang; Junmei Chen; Minhua Ling; José A López; Dominic W Chung; Xiaoyun Fu
Journal:  J Biol Chem       Date:  2014-11-24       Impact factor: 5.157

Review 9.  Pathophysiological Function of ADAMTS Enzymes on Molecular Mechanism of Alzheimer's Disease.

Authors:  Murat Serdar Gurses; Mustafa Numan Ural; Mehmet Akif Gulec; Omer Akyol; Sumeyya Akyol
Journal:  Aging Dis       Date:  2016-01-11       Impact factor: 6.745

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.